IGC Pharma的第二阶段试验, 测试基于THC的阿尔茨海默氏性痴呆症药物IGC-AD1, IGC Pharma's Phase 2 trial for its THC-based Alzheimer’s drug IGC-AD1 hits 50% enrollment, aiming to treat agitation in patients.

IGC Pharma(IGC Pharma)于2025年9月22日宣布, 其第二阶段CALMA测试IGC-AD1(一种低剂量THC疗法)已达50%, IGC Pharma announced on September 22, 2025, that its Phase 2 CALMA trial for IGC-AD1, a low-dose THC-based therapy, has reached 50% enrollment in a study assessing its potential to treat agitation in Alzheimer’s patients. 多中心、双盲试验正在评估该药物减少激动症的能力 — — 一种常见和难以治疗的症状 — — 同时也针对老年痴呆症的病理。 The multicenter, double-blind trial is evaluating the drug’s ability to reduce agitation—a common and difficult-to-treat symptom—while also targeting underlying Alzheimer’s pathologies. 佛罗里达、安大略、罗得岛、俄克拉何马、不列颠哥伦比亚和波多黎各的新审判地点扩大了准入和多样性。 New trial sites in Florida, Ontario, Rhode Island, Oklahoma, British Columbia, and Puerto Rico have expanded access and diversity. 该公司仍然有望在2026年初完成招生,预期届时将报告结果。 The company remains on track to complete enrollment in early 2026 and expects to report results by then. IGC Pharma在药物开发中使用人工智能,正在推进多个神经退化和代谢紊乱方案。 IGC Pharma, which uses artificial intelligence in drug development, is advancing multiple programs for neurodegenerative and metabolic disorders. 前瞻性说明包括与管制核准、临床结果和与大麻有关的政策演变有关的风险。 Forward-looking statements include risks related to regulatory approval, clinical outcomes, and evolving cannabis-related policies.